Anavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX®2-73 in Mild-to-Moderate Alzheimer’s Disease Patients; Conference call today at 8:30am ET

ANAVEX2-73 demonstrates desirable PK/PD properties, describing the relationship between drug concentration and the effect observed Anavex is incorporating advanced Artificial Intelligence platform for the analysis of Phase 2a results with the aim to increase the chances of success in forthcoming Phase 2/3 study NEW YORK, October 12, 2017 – Anavex Life Sciences Corp. (Nasdaq: AVXL)…